الفهرس 
ANATOMY OF THE OVARYOnly 14 pages are availabe for public view
 |  | from | 124 |  |  |
| | | from | 124 | | |
Abstract
Ovarian cancer is one of the most common malignancies of the female genital tract and is the leading cause of death from gynecological cancer.
Early detection of OC represents the cornerstone in the management plan where PET/CT can play a major role, as combined PET/CT gives a higher sensitivity and specificity (100,92.5% respectively ) than US, CT, MRI & PET alone.
This gives the chance to limit the role of exploratory laparotomy when a pelvic tumour is suspected.
PET/CT provides an optimal 1ry cytoreductive surgery, as it helps the surgeon to find accurately the sites where the tumour has to be removed.
PET/CT may be helpful in detecting small recurrent lesions in patients in whom post-therapeutic alterations in anatomy may make it difficult to interpret conventional imaging studies.
Combination between PET/CT and CA125 titer gives a sensitivity of 97.8%, In 19.5 % of patients, PET/CT can detect recurrent ovarian cancer before elevation of CA 125.
Intraoperative PET/CT is a new promising technique that allows for confirmation of complete anatomic and metabolic cytoreduction in patients with recurrent ovarian cancer.
PET has been evaluated as a substitute for second-look operation in ovarian cancer patients with a complete clinical, radiographic, and serologic response following primary surgery and chemotherapy.
As any imaging modality PET/CT has some limitations one of the major limitation is the cost of this relatively new technique, Other limitation are explored in differentiation between tumour and areas of inflammation or infection, also limited in detecting peritoneal carcinomatosis, low grade malignancies and, malignancy in pre-menopausal women.
In conclusion PET/CT has an important role in diagnosis, staging and follow up of cases of ovarian cancer regarding response to treatment or recurrence. In addition the technical advantages of PET/CT, such as better contrast and resolution, shorter scanning time as well as better patient compliance can’t be ignored.
Lastly, the role of PET imaging will continue to expand as more indications are approved and newer more tumour-specific radiopharmaceutical agents are developed.